알포트 증후군 : 시장 인사이트, 역학 및 시장 예측(2036년)

Alport Syndrome Insights and Trends

• According to DelveInsight's analysis, Alport Syndrome market size was found to be around USD 20 million in the leading markets (the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan) in 2025.
• Alport syndrome is a rare inherited kidney disorder caused by mutations in type IV collagen genes (COL4A3, COL4A4, COL4A5), leading to structural abnormalities of the glomerular basement membrane and characterized by progressive renal impairment, sensorineural hearing loss, and eye abnormalities.
• It is a lifelong condition with an estimated prevalence of ~1 in 5,000-10,000 individuals, though the true burden is likely underestimated due to underdiagnosis and recognition of a broader "Alport spectrum", encompassing both severe and milder phenotypes.
• The disease exhibits heterogeneous inheritance patterns, predominantly X-linked (~80%), with males typically experiencing earlier onset and faster progression to end-stage renal disease (ESRD), while females and autosomal forms show variable but still clinically significant disease progression.
• The underlying pathophysiology involves defective type IV collagen assembly, resulting in progressive glomerular basement membrane thinning, splitting, and fibrosis, ultimately driving chronic kidney disease progression and systemic manifestations.
• Diagnosis remains challenging and is frequently delayed due to phenotypic variability and overlap with other renal conditions (e.g., IgA nephropathy), with genetic testing now considered the gold standard but still not universally implemented in routine clinical practice.
• The current treatment landscape is largely supportive and non-curative, relying on ACE inhibitors, ARBs, and more recently SGLT2 inhibitors to reduce proteinuria and slow renal decline, with dialysis and kidney transplantation required in advanced stages.
• There are currently no disease-specific approved therapies for Alport syndrome, and treatment relies on repurposed chronic kidney disease interventions, including ACE inhibitors, angiotensin receptor blockers, and supportive care, with kidney transplantation required in advanced stages.
• Despite advances, significant unmet needs persist, including lack of curative therapies, limited genotype-targeted treatments, absence of robust biomarkers for early progression, and continued diagnostic delays, collectively underscoring the need for innovative, disease-modifying strategies.

Alport Syndrome Market Size and Forecast in the 7MM

• 2025 Alport Syndrome Market Size: ~USD 20 million
• Alport Syndrome Growth Rate (2026-2036): ~39% CAGR

DelveInsight's 'Alport Syndrome - Market Insights, Epidemiology and Market Forecast - 2036' report delivers an in-depth understanding of the Alport Syndrome, historical and forecasted epidemiology, as well as the Alport Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

The Alport Syndrome market report delivers a comprehensive analysis of the current treatment landscape, including standards of care, clinical practices, and evolving therapeutic algorithms. It evaluates Alport Syndrome patient burden trends, revenue & market share dynamics, peak patient share & therapy uptake analysis, and provides an in-depth market size assessment, and growth rate projections (Historical & Forecast 2022-2036) across global regions. The report highlights key unmet medical needs in Alport Syndrome and maps the competitive and clinical landscape to uncover high-value opportunities, providing a clear outlook on future market growth potential.

Key Factors Driving the Alport Syndrome Syndrome Market

Increasing recognition and diagnosis of Alport syndrome

Improved access to genetic testing and heightened clinical awareness are driving earlier and more accurate diagnosis of Alport syndrome. This is contributing to a growing identified patient population and increasing the need for targeted, long-term disease management strategies.

Advancements in genetic diagnostics and hereditary disease detection

Progress in genetic screening technologies, along with greater emphasis on family history and inherited kidney disorders, is enhancing the detection of mutations associated with Alport syndrome. These developments are supporting earlier intervention and improved disease monitoring, reinforcing the demand for effective therapeutic approaches.

Alport Syndrome Understanding and Treatment Algorithm

Alport Syndrome Overview and Diagnosis

Alport syndrome is a hereditary disorder caused by mutations in type IV collagen genes (COL4A3, COL4A4, COL4A5), affecting basement membranes of the kidneys, ears, and eyes. It presents with early hematuria and progressive kidney dysfunction that can lead to renal failure, often accompanied by hearing loss and ocular abnormalities. The disease occurs in X-linked, autosomal recessive, and autosomal dominant forms, with X-linked being the most common and severe in males. Diagnosis relies on clinical features, family history, biopsy findings, and increasingly genetic testing. There is no curative treatment; management focuses on slowing disease progression using supportive therapies, though many patients eventually require dialysis or kidney transplantation.

The diagnostic approach to Alport syndrome integrates clinical suspicion, laboratory testing, and advanced genetic analysis. It is typically suspected in individuals with persistent hematuria, family history of kidney disease, early hearing loss, or unexplained renal impairment. Initial evaluation includes urine and blood tests to assess hematuria, proteinuria, and kidney function, though these findings are not disease-specific. Kidney biopsy can provide supportive evidence through structural and collagen abnormalities, while skin biopsy may aid in select cases. However, genetic testing has become the gold standard, enabling definitive identification of mutations in COL4A3, COL4A4, and COL4A5 genes and determination of inheritance patterns. Complementary assessments such as audiometry and ophthalmologic evaluation further support diagnosis and disease monitoring.

Current Alport Syndrome Treatment Landscape

Alport syndrome management is primarily supportive and aimed at slowing disease progression, as no curative therapy exists. Treatment is individualized, with renin-angiotensin-aldosterone system (RAAS) inhibition forming the cornerstone angiotensin-converting enzyme (ACE) inhibitors are first-line due to their antihypertensive, antiproteinuric, and nephroprotective effects, while angiotensin receptor blockers (ARBs) are used in patients who are intolerant or unresponsive. Additional supportive measures, including diuretics, may be used based on proteinuria severity. Despite these interventions, many patients progress to end-stage kidney disease, requiring dialysis or kidney transplantation, the latter offering favorable outcomes. Adjunct management includes hearing aids for sensorineural hearing loss and ophthalmologic interventions when needed. Emerging approaches such as gene and stem cell therapies are under investigation but remain experimental.

Alport Syndrome Unmet Needs

The section "unmet needs of Alport Syndrome" outlines the critical gaps between the current state of patient care, diagnosis, and the ideal & effective management of the disease. It highlights the obstacles experienced by patients, clinicians, and researchers and identifies potential solutions for future progress.

1. Challenges to early diagnosis

2. Lack of approved treatment options

3. Need for new therapeutic targets and treatment approaches, and others.....

Alport Syndrome Epidemiology

Key Findings from Alport Syndrome Epidemiological Analysis and Forecast

• Alport syndrome is caused by mutations in the genes responsible for alpha-3, alpha-4, and alpha-5 chains of type IV collagen. The prevalence of Alport syndrome is not well-documented but is believed to be found in about 1 in every 50,000 live births worldwide.
• The total diagnosed prevalent cases of Alport syndrome in the 7MM were 29,500 cases in 2025 and are projected to rise by 2036.
• In 2025, EU4 and the UK accounted for 7,000 cases in males and 6,400 cases in females. These cases are expected to increase to 9,441 cases and 8,715 cases in males and females, respectively by 2036.
• In 2025, the 18 years and above age segment accounted for the highest number of cases in EU4 and the UK i.e, 11,400 cases whereas, the 12-17 years age segment had the least number of cases accounting for 870 cases. These cases are expected to increase by 2036.

Alport Syndrome Drug Analysis & Competitive Landscape

The alport syndrome drug chapter provides a detailed, market-focused review of approved therapies and the emerging pipeline across Phase I-III clinical trials. It covers the mechanism of action, clinical trial data, patents, collaborations, and strategic partnerships, upcoming key catalysts for each therapy, along with their advantages, limitations, and recent developments. This section offers critical insights into the alport syndrome treatment landscape, supporting market assessment, competitive analysis, and growth forecasting for the alport syndrome therapeutics market.

Alport Syndrome Pipeline Analysis

ELX-02: Eloxx Pharmaceuticals

Eloxx's lead investigational product candidate, ELX-02, is a small molecule drug candidate designed to restore the production of full-length functional proteins. It is a synthetic aminoglycoside administered through the subcutaneous route and inhalational route. It optimizes ribosomal read-through of premature termination codons (PTC), through which full-length functional proteins can be produced. It acts by targeting CFTR. Preclinical studies support ELX-02 activity in nonsense mutation genetic kidney diseases.

Alport Syndrome Key Players, Market Leaders and Emerging Companies

• Bayer
• Eloxx Pharmaceuticals
• Chinook Therapeutics
• Calliditas Therapeutics, and others

Alport Syndrome Market Outlook

According to the National Kidney Foundation, Alport syndrome is a disease that damages the tiny blood vessels in the kidneys. It can lead to kidney disease and kidney failure and also cause hearing loss and problems within the eyes. This condition is an inherited disease, with X-linked being the most common of it, and accounts for approximately 80% of the total cases. In the absence of intervention, approximately 90% of males experience kidney failure by the age of 40, whereas females less commonly and more gradually progress to kidney failure.

Despite the significant severity of this condition, there is currently no specific treatment for Alport syndrome. The focus is on strategies to limit proteinuria and kidney disease progression. Management options encompass the use of angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARBs) to address proteinuria, hypertension, and chronic kidney disease (CKD). Depending on the severity of proteinuria, diuretics may also be employed. While these treatments can potentially postpone the onset of renal impairment, the majority of individuals affected by this syndrome eventually undergo a dialysis or kidney transplant.

• Over the next decade, improved early diagnosis and treatment advancements are expected to raise the age at which kidney failure manifests in individuals with Alport syndrome. Additional benefits are anticipated from novel therapies that can complement ACE inhibition. While safe and effective curative therapies are within the realm of possibility, notable challenges must be addressed to transform these possibilities into reality.
• In 2025, the the US accounted for the maximum share of the total market in the 7MM, i.e.,59%, followed by Germany capturing nearly 9% share. The total market size in the 7MM for Alport Syndrome was estimated to be USD 20 million in 2025, which is expected to show positive growth by 2036.
• Among the 7MM countries, the United States accounted for the largest market size for Alport syndrome. The market size for Alport Syndrome was USD 12 million in the United States in 2025. Due to the emergence of novel therapies, the overall market size of Alport Syndrome would experience an increase in the United States during the forecast period.
• Among EU4 and the UK, Germany will capture the maximum revenue share, followed by France and the UK by 2036.

Drug Class/Insights into Leading Emerging and Marketed Therapies

The alport syndrome market comprises regenerative therapies, small molecules, and other emerging modalities, each targeting key mechanisms such as peripheral nerve hyperexcitability, ion channel modulation, and neuroprotection.

• Small molecules: This segment includes agents designed to target underlying disease pathways in Alport syndrome, with the aim of slowing renal disease progression, reducing proteinuria, and improving overall clinical outcomes.

These emerging therapies reflect a shift toward mechanism-based, disease-specific approaches, moving beyond symptomatic management to address the underlying neurobiology of 22q11.2 deletion syndrome.

Alport Syndrome Drug Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during the forecast period (2026-2036). The analysis covers the alport syndrome drug's uptake, performance at peak, factors affecting performance during prime years of growth, patient uptake by therapy, and anticipated sales generated by each drug.

Detailed insights into emerging therapies' drug uptake are included in the report.

Market Access and Reimbursement of Approved Therapies in Alport Syndrome

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Reimbursement is a crucial factor that affects the drug's access to the market. Often, the decision to reimburse comes down to the price of the drug relative to the benefit it produces in treated patients. To reduce the healthcare burden of these high-cost therapies, many payment models are being considered by payers and other industry insiders.

NOTE: Further Details are provided in the final report....

Alport Syndrome Therapies Price Scenario & Trends

Pricing and analogue assessment of alport syndrome therapies highlights evolving price dynamics structures. This section summarizes the cost of approved treatments, the closest and most appropriate analogue selection for emerging therapies, and the understanding of how pricing influences market access, adherence, and long-term uptake.

Industry Experts and Physician Views for Alport Syndrome

To keep up with alport syndrome market trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts were contacted for insights on alport syndrome emerging therapies, evolving treatment landscape, patient adherence to conventional therapies, therapy switching trends, drug adoption and uptake, accessibility challenges, and epidemiology and real-world prescription patterns in alport syndrome, including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.

DelveInsight's analysts connected with 10+ KOLs to gather insights at the country level. Centers such as University of Michigan Hospitals & Health Centers, University of Duisburg-Essen, King's College London, and University of Verona, etc. were contacted. Their opinion helps understand and validate current and emerging alport syndrome therapies, highlight unmet medical needs, provide epidemiological context, and support strategic decisions for market access, therapy adoption, and pipeline prioritization in alport syndrome.

Qualitative Analysis: SWOT and Conjoint Analysis

We perform qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and conjoint analysis.

In the SWOT analysis of Alport Syndrome, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.

Conjoint analysis analyzes emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

The team of analysts analyzes promising emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. In efficacy, the trial's primary and secondary outcome measures are evaluated, whereas the therapies' safety is evaluated, wherein the acceptability, tolerability, and adverse events are mainly observed. In addition, the scoring is also based on the route of administration, order of entry, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Scope of the Report:

• The report covers a segment of key events, an executive summary, a descriptive overview of alport syndrome, explaining its causes, signs and symptoms, pathogenesis, and currently available treatments.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging treatments, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the alport syndrome market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM alport syndrome market.

Report Insights

• Alport syndrome Patient Population Forecast
• Alport syndrome Therapeutics Market Size
• Alport syndrome Pipeline Analysis
• Alport syndrome Market Size and Trends
• Alport syndrome Market Opportunity (Current and forecasted)

Report Key Strengths

• Epidemiology-based (Epi-based) Bottom-up Forecasting
• Artificial Intelligence (AI)-Enabled Market Research Report
• 11-Year Forecast
• Alport syndrome Market Outlook (North America, Europe, Asia-Pacific)
• Patient Burden Trends (By Geography)
• Alport syndrome Treatment Addressable Market (TAM)
• Alport syndrome Competitive Landscape
• Alport syndrome Major Companies Insights
• Alport syndrome Price Trends and Analogue Assessment
• Alport syndrome Therapies Drug Adoption/Uptake
• Alport syndrome Therapies Peak Patient Share Analysis

Report Assessment

• Alport syndrome Current Treatment Practices
• Alport syndrome Unmet Needs
• Alport syndrome Clinical Development Analysis
• Alport syndrome Emerging Drugs Product Profiles
• Alport syndrome Market attractiveness
• Alport syndrome Qualitative Analysis (SWOT and Conjoint analysis)

FAQs:

Market Insights

• What was the Alport syndrome market size, the market size by therapies, market share (%) distribution in 2025, and what would it look like by 2036? What are the contributing factors for this growth?
• What are the anticipated pricing variations among different geographies for the emerging therapies in the future?
• What can be the future treatment paradigm of Alport syndrome?
• What are the disease risks, burdens, and unmet needs of Alport syndrome? What will be the growth opportunities across the 7MM concerning the patient population with Alport syndrome?
• Who is the major future competitor in the market, and how will the competitors affect their market share?
• What are the current options for the treatment of Alport syndrome? What are the current guidelines for treating Alport syndrome in the US, Europe, and Japan?

Reasons to Buy:

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the Alport syndrome market.
• Bottom up forecasting builds from the affected population to product forecasts, delivering a robust, data driven approach ideal for new therapies and novel classes.
• Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• To understand KOLs' perspectives on the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.
• This Artificial Intelligence (AI) enabled report summarizes and simplifies complex datasets within the report into clear, actionable insights for stakeholders, investors, and healthcare providers, enabling faster, data driven decisions.

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary of Alport Syndrome

4. Key Events

• 4.1. Upcoming Key Catalyst
• 4.2. Key Conferences and Meetings
• 4.3. Key Transactions and Collaborations
• 4.4. News Flow

5. Epidemiology and Market Forecast Methodology

6. Alport Syndrome Market Overview at a Glance

• 6.1. Clinical Landscape Analysis (by Phase, MoA, and RoA)
• 6.2. Market Share (%) Distribution of Alport Syndrome by Therapies in the 7MM in 2025
• 6.3. Market Share (%) Distribution of Alport Syndrome by Therapies in the 7MM in 2036

7. Disease Background and Overview of Alport Syndrome

• 7.1. Introduction
• 7.2. Cause and Inheritance
• 7.3. Signs and Symptoms
• 7.4. Complications
• 7.5. Pathophysiology
• 7.6. Diagnosis
  • 7.6.1. Differential Diagnosis
  • 7.6.2. Diagnosis Algorithm
  • 7.6.3. Diagnosis Guidelines

8. Treatment

• 8.1. Treatment Algorithm
• 8.2. Treatment Guidelines
  • 8.2.1. Practical Guidelines for Managing Adults with Alport Syndrome
  • 8.2.2. Towards a Safety Net For Management of Alport Syndrome: Guidelines

9. Epidemiology and Patient Population of Alport Syndrome

• 9.1. Key Findings
• 9.2. Assumptions and Rationale
• 9.3. Total Prevalent Cases of Alport Syndrome in the 7MM
• 9.4. Total Diagnosed Prevalent Cases of Alport Syndrome in the 7MM
• 9.5. The United States
  • 9.5.1. Total Prevalent Cases of Alport syndrome in the United States
  • 9.5.2. Total Diagnosed Prevalent of Alport syndrome in the United States
  • 9.5.3. Gender-specific Cases of Alport syndrome in the United States
  • 9.5.4. Age-specific Cases of Alport syndrome in the United States
  • 9.5.5. Type-specific Cases of Alport syndrome in the United States
• 9.6. EU4 and the UK
  • 9.6.1. Total Prevalent Cases of Alport syndrome in EU4 and the UK
  • 9.6.2. Total Diagnosed Prevalent of Alport syndrome in EU4 and the UK
  • 9.6.3. Gender-specific Cases of Alport syndrome in EU4 and the UK
  • 9.6.4. Age-specific Cases of Alport syndrome in EU4 and the UK
  • 9.6.5. Type-specific Cases of Alport syndrome in EU4 and the UK
• 9.7. Japan
  • 9.7.1. Total Prevalent Cases of Alport syndrome in Japan
  • 9.7.2. Total Diagnosed Prevalent of Alport syndrome in Japan
  • 9.7.3. Gender-specific Cases of Alport syndrome in Japan
  • 9.7.4. Age-specific Cases of Alport syndrome in Japan
  • 9.7.5. Type-specific Cases of Alport syndrome in Japan

10. Patient Journey of Alport Syndrome

11. Emerging Therapies

• 11.1. Emerging Competitive Landscape
• 11.2. ELX-02: Eloxx Pharmaceuticals
  • 11.3.1. Product Description
  • 11.3.2. Other Developmental Activities
  • 11.3.3. Clinical Developmental Activities
    • 11.3.3.1. Clinical trial information
  • 11.3.4. Safety and Efficacy
  • 11.3.5. Analyst Views

12. Alport Syndrome: 7MM Analysis

• 12.1. Key Findings
• 12.2. Market Outlook
• 12.3. Conjoint Analysis
• 12.4. Key Market Forecast Assumptions
  • 12.4.1. Cost Assumptions and Rebates
  • 12.4.2. Pricing Trends
  • 12.4.3. Analogue Assessment
  • 12.4.4. Launch Year and Therapy Uptakes
• 12.5. Total Market Size of Alport Syndrome in the 7MM
• 12.6. The United States
  • 12.6.1. Total Market Size of Alport Syndrome in the United States
  • 12.6.2. Market Size of Alport Syndrome by Therapies in the United States
• 12.7. EU4 and the UK
  • 12.7.1. Total Market Size of Alport Syndrome in EU4 and the UK
  • 12.7.2. Market Size of Alport Syndrome by Therapies in EU4 and the UK
• 12.8. Japan
  • 12.8.1. Total Market Size of Alport Syndrome in Japan
  • 12.8.2. Market Size of Alport Syndrome by Therapies in Japan

13. KOL Views of Alport Syndrome

• 13.1. Expert/KOL Interview Highlights

14. Unmet Needs of Alport Syndrome

15. SWOT Analysis of Alport Syndrome

16. Market Access and Reimbursement of Alport Syndrome

• 16.1. The US
• 16.2. In EU4 and the UK
  • 16.2.1. Germany
  • 16.2.2. France
  • 16.2.3. Italy
  • 16.2.4. Spain
  • 16.2.5. United Kingdom
• 16.3. Summary and Comparison of Market Access and Pricing Policy Developments in 2025

17. Appendix

• 17.1. Bibliography
• 17.2. Report Methodology

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight